StockNews.AI
ARDX
StockNews.AI
124 days

Ardelyx to Report First Quarter 2025 Financial Results on May 1, 2025

1. ARDX will hold a conference call on May 1, 2025. 2. The call will discuss Q1 2025 financial results and business updates. 3. ARDX commercializes two products, IBSRELA and XPHOZAH, in the U.S. 4. Tenapanor is approved for hyperphosphatemia in China and Japan. 5. Webcast of the call will be available for 30 days post-event.

3m saved
Insight
Article

FAQ

Why Bullish?

Positive financial updates and product approvals generally boost investor confidence in biotech firms.

How important is it?

The conference call's content can significantly influence near-term market reactions for ARDX.

Why Short Term?

The upcoming call may lead to immediate fluctuations in ARDX's stock price based on investor sentiment.

Related Companies

IBRXVRTXAMGN
Conference call scheduled for 4:30 p.m. Eastern Time April 17, 2025 08:00 ET  | Source: Ardelyx, Inc. WALTHAM, Mass., April 17, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced it will hold a conference call on Thursday, May 1, 2025, at 4:30 p.m. Eastern Time to discuss financial results and provide a business update from the first quarter of 2025. To participate in the conference call, please dial (877) 346-6112 (domestic) or (848) 280-6350 (international) and ask to be joined into the Ardelyx call. Live audio of the conference call will be simultaneously webcast and will be available under the Investors section of the company's website at www.ardelyx.com. The webcast will be archived and available for replay for 30 days following the call. About ArdelyxArdelyx was founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs. Ardelyx has two commercial products approved in the United States, IBSRELA® (tenapanor) and XPHOZAH® (tenapanor). Ardelyx has agreements for the development and commercialization of tenapanor outside of the U.S. Kyowa Kirin commercializes PHOZEVEL® (tenapanor) for hyperphosphatemia in Japan. A New Drug Application for tenapanor for hyperphosphatemia has been approved in China with Fosun Pharma. Knight Therapeutics commercializes IBSRELA in Canada. For more information, please visit https://ardelyx.com/ and connect with us on X (formerly known as Twitter), LinkedIn and Facebook. Investor and Media Contacts: Caitlin Lowieclowie@ardelyx.com

Related News